Massive Growth in Psoriasis Treatment Market Set to Witness Huge Growth by 2026 | Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO…

Psoriasis Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=280493

Top Key Players Profiled in This Report:

Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO Pharma A/S, Eli Lilly and Company, UCB S.A., Johnson and Johnson Services, Inc., CELGENE CORPORATION, Pfizer Inc.,, AbbVie Inc., Merck and Co., Inc., _x000D_,

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get Best Discount on this Premium Report at:

https://www.a2zmarketresearch.com/discount?reportId=280493

Reasons for buying this report:

Table of Contents:

Global Psoriasis Treatment Market Research Report

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=280493

See the rest here:

Massive Growth in Psoriasis Treatment Market Set to Witness Huge Growth by 2026 | Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO...

New Potential Advances In Treating Psoriasis: A Skin Condition That Affects 125+ Million People – Forbes

Although psoriasis has been a well-recognized skin condition for many years, there has been significant progress over the last decade on effective therapeutic models and treatment modalities for this autoimmune condition. But what exactly is this condition that affects nearly 125 million people across the globe and more than 8 million Americans? As explained by the Centers for Disease Control and Prevention (CDC), psoriasisis a chronic autoimmune skin disease that speeds up the growth cycle of skin cells. This often emanates as patches of thick red skin and silvery scales which are typically found on the elbows, knees, scalp, lower back, face, palms, and soles of feet, but can affect other places (fingernails, toenails, and mouth). The condition may present as a wide spectrum of severity and skin symptoms. Furthermore, psoriasis is often linked to more severe and chronic medical conditions, such as psoriatic arthritis, diabetes, and cardiac issues, to name a few. Psoriatic arthritis is especially common in those that have psoriasis, resulting in inflammation, joint pain, and stiffness that may inevitably lead to severe mobility issues.

Given the seriousness of this condition as well as its widespread prevalence, significant research and efforts have gone into finding sustainable treatments. There are entire labs, fellowships, clinical platforms, and organizations dedicated to helping individuals with psoriasis. Notably, the past decade has seen significant improvements in various treatment modalities, ranging from topical treatments, to injections and oral medications. There are many different mechanisms of action and physiological targets for psoriasis treatments; a few examples include reducing inflammation, slowing skin growth, or altering the immune system.

Phototherapy has received a lot of attention and research in the past few years. Per The National Psoriasis Foundation, the basic premise of phototherapy involves exposing the skin to wavelengths of ultraviolet A light (UVA) or ultraviolet B light (UVB) under the supervision of a health care provider to treat psoriasis. The idea behind this treatment is that UV light penetrates the top layers of skin and stops the skin cells from growing too quickly, leading to improvement in psoriasis symptoms.

Using phototherapy to help with psoriasis symptoms.

More recent developments are also gaining traction. Late last week (July 16th), The New England Journal of Medicine (NEJM) published an article titled Trial of Roflumilast Cream for Chronic Plaque Psoriasis. The article discusses a clinical trial in which researchers tested the use of Roflumilast cream, which contains phosphodiesterase type 4 (PDE-4) inhibitor, as a potentially viable and sustainable topical treatment modality for plaque psoriasis. The study describes that 331 patients were randomized: 109 were assigned to roflumilast 0.3% cream, 113 to roflumilast 0.15% cream, and 109 to vehicle [placebo] cream. The results indicated that Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks. However, the authors explicitly conclude that Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis. This is often the case with new and cutting-edge therapieslarger and well-repeated, evidence-backed trials are required in order to truly understand a treatments efficacy and safety.

Another fascinating research trial by Harvard Universitys Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS) was published yesterday, describing the use of small interfering RNA (siRNA) to help control psoriasis-related activity at the genetic level. The article explains that using siRNA based therapies on the skin has traditionally been challenging, given the compounds instability and the skins barrier function. However, in this study, the authors claim that they found a way to effectively deliver the treatment molecule into the skin, resulting in down-regulation of psoriasis-related signals. Though more testing will be required to fully determine the safety and efficacy of this treatment model, this new development may potentially open the doors to a new way of delivering topical medications.

A dermatologist applies a therapeutic ointment to the affected skin of a patient with psoriasis.

Indeed, psoriasis is a very serious and life-altering condition for many people. With such a wide variety of symptoms and presentations, patients must ultimately consult with trained and certified medical professionals on what treatment and therapy is best for their specific situation. As many new therapies and methods of treatment continue to emerge, government leaders, the scientific community, medical professionals, and patients must maintain a high level of scrutiny to ensure that enough testing and evidence-based research is done in order to ultimately maintain the highest emphasis on patient safety. Nonetheless, the fact that many institutions and experts are continuing to work on creating more effective and practical therapies provides hope for the millions of people affected by this condition.

The content of this article is not implied to be and should not be relied on or substituted for professional medical advice, diagnosis or treatment by any means, and is not written or intended as such. This content is for information purposes only. Consult with a trained medical professional for medical advice.

Here is the original post:

New Potential Advances In Treating Psoriasis: A Skin Condition That Affects 125+ Million People - Forbes

Brave woman tells story of how New Years Eve kiss triggered incurable skin condition psoriasis – The Sun

WHEN a kiss with someone suffering from tonsilitis triggered an incurable skin condition, Aimee Godden turned to social media for support.

Here, Aimee and two other women tell Rebecca Pascoe how Instagram helped them to embrace their skin.

10

Aimee is expecting a baby with chef Ryan McQueen, 35. The 34-year-old artist from Ashford, Kent, says:

"I first developed mild psoriasis at the age of 14. It was a few patches which I easily hid under clothes.

"I didnt worry much about it until 2018 when I had a severe outbreak.

"Incredibly, it was triggered by a New Years Eve kiss with someone who, unknown to me, had tonsilitis.

10

"I caught the virus but also developed patches of dry skin on my forehead, cheeks and chest. Soon, the patches were the size of 2p pieces and all over my arms, thighs, and my back.

"A doctor diagnosed me with guttate psoriasis and said the tonsilitis had triggered it.

"I was devastated to be told there was no cure and terrified I would look like this for ever. My face was completely different to the one Id known my whole life.

"I moved back in with my mum and didnt want to go out, see friends or look in the mirror.

10

"I couldnt face telling friends and family so I decided to explain to them on Instagram. Somehow the post got shared, and the reaction from strangers was incredible.

"In public, people have pointed at my face and said urgh but online Ive had such a positive response.

"People with psoriasis say Ive given them confidence, but I say the same thing back to them. Its a positive cycle, and we help each other.

"You expect acceptance and support from friends and family. And when it comes from strangers, it feels so genuine.

"Psoriasis can take over your life. Its uncomfortable, itchy and it burns.

"Clothes cause friction and at times I cant even wear a bra. Make-up can also aggravate the skin.

"Psoriasis on my scalp made my hair fall out, so sometimes I wear wigs. Ive even had toenails removed. Creams soothe it, and light therapy helped.

"Sunshine, a healthy diet and avoiding alcohol all help me manage it. But it can turn severe at any time.

10

"My first night out after the major outbreak in June 2018 was intimidating.I noticed some blokes looking over and laughing.

"When one of them asked to buy me a drink I was shocked, and asked him if he could see my skin.

"He said yes, and that I was beautiful. Weve been together ever since and were expecting our baby in October.

Id worried psoriasis would stop me finding love. But I feel so much love in my life now."

Natalie Ambersley an executive assistant from Ilford, Essex, has vitiligo, where a lack of pigment causes white patches on the skin.

She now campaigns for Changing Faces, a charity that supports people with visible differences. Natalie, 38, says:

10

"I was two when my mum noticed white patches on the back of my hand. I was diagnosed with vitiligo two years later. It wasnt well known then. I didnt know anyone like me.

"When I was a baby, someone asked my mum why shed let me be burned.

"At age eight, a boy at school went to touch my arm but stopped and said: I dont want to catch your skin.

"As a teenager, I felt isolated. I didnt want to show my skin, so even when it was hot I wore trousers and long sleeves. I loved PE but hated wearing the skirt, so made up excuses not to take part.

10

"As a teenager you compare yourself to girls in magazines, but none of them looked like me.

"In my 20s I used make-up and fake tan to try to cover the patches. On dates I would hide my hands under the table and wear long-sleeved tops.

"Ive been trying treatments since I was four steroid creams, homeopathy and when I was older months of light therapy to stimulate the pigment in my skin.

"But when I was 30, I shared my story on Instagram and people with vitiligo from all around the world got in touch.

10

"Ive now got around 2,500 followers and we share advice for example, about which suncream is effective. Id never had friends with vitiligo before but now I see people Ive met on Instagram for a glass of wine.

"Now I love my vitiligo, it makes me interesting. It gives me a story to tell, which is painted on my skin. I cant change it so had to celebrate it.

"I always felt I was missing something but now I feel beautiful and unique."

Make-up artist Bianca Lawrence developed keloids enlarged, raised areas of scar tissue on her jawline, ears, chest and back after being prescribed acne medication.

Bianca, 26, who lives in Bradford, says: "When I was about 12 I was prescribed Roaccutane for my acne.

10

"At first, my skin came out in what looked like little pimples. By the time I was 16 they were big keloids.

"One behind my left ear was the size of a golf ball. They gave me shooting pains and they itch and burn.

"For ten years, I battled with confidence issues, covering up the keloids when out in public.

"Strangers would stare, make rude remarks, point and laugh. Someone even said I was ugly and should kill myself. At times, I was really depressed. But eventually, I decided I wanted to out my scars on Instagram before doing it in public.

10

"So in February 2017, I posted two pictures one which I edited to cover up the scars, and another showing them.

"I was scared about the reaction, but I couldnt believe the positive responses.

"Since then, Ive been followed by loads of people around the world with the same condition. Ive got 6,200 followers.

"After getting that acceptance online, I felt more confident to show my scars in public.

10

BARGAIN BRONZERWoman reveals hack on how to get perfect glowing skin WITHOUT fake tan

COSY UPShoppers are going mad for B&M's 50p throws and blankets in their huge summer sale

BUILDING CONFIDENCEMum shares adorable pay packet builders gave to her six-year-old

WASH 'N' LEAVEMum-of-4 reveals HUGE lockdown laundry pile that built up over 2 months

BUSSING ITWe live on a bus that costs 6 a day to run - life on the road is stress-free

DREAM ROOMDoting mum revamps daughter's bedroom with pretty bargains from B&M, eBay & Asda

"I even put glitter on them sometimes so they shine I dont want to hide them any more. I feel so free now. I can be myself."

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAILexclusive@the-sun.co.uk

Link:

Brave woman tells story of how New Years Eve kiss triggered incurable skin condition psoriasis - The Sun

Treatment significantly reduces symptoms of psoriasis in mice – Harvard Gazette

Psoriasis, a chronic skin condition that causes itchy, red, scaly patches, afflicts more than 8 million Americans and 125 million people worldwide. Small molecule-based drugs like steroids can penetrate the skin to treat the condition, but they can cause skin irritation and thinning and their efficacy can decrease over time. Antibodies that target specific inflammation-related molecules associated with psoriasis have been developed, but because they cannot be delivered via the skin, they are injected using needles and syringes, which limits their acceptance and can have negative systemic side effects.

A team of researchers at Harvards Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS) has circumvented these limitations by using an ionic liquid (IL) combination to successfully deliver a small interfering RNA (siRNA)-based treatment directly to the skin in a mouse model of psoriasis, significantly reducing levels of inflammatory cytokines and symptoms of psoriasis without systemic side effects. The research is published today in Science Advances.

Compared to other technologies that have demonstrated delivery of nucleic acids to the skin, our IL platform offers unique opportunities in terms of tunability, an excellent safety profile, and economical scale-up, said first author Abhirup Mandal, a former postdoctoral fellow at the Wyss Institute and SEAS who is now a senior research scientist at CAGE Bio. We think that effective topical delivery of macromolecules will revolutionize the treatment options for debilitating dermatological disorders like psoriasis.

Synthetic siRNAs are non-coding double-stranded RNA molecules that are routinely used in biological research to silence a target gene by destroying the genes RNA transcripts. This ability also makes them very attractive candidates for treating diseases and disorders without modifying the DNA in a patients cells. However, their use in medicine has been hampered because RNAs are large, hydrophilic molecules, and therefore have a hard time crossing cells hydrophobic membranes.

The team at the Wyss Institute and SEAS tackled that challenge using a recently discovered class of material called ionic liquids (ILs), which are essentially salts that are liquid at room temperature. Based on earlier research investigating the interactions of ILs with lipids, the researchers had a hunch that ILs could stabilize siRNAs and improve their penetration across lipid-based cell membranes, enabling localized gene silencing.

The team first created a library of different ILs, then tested combinations of them to see which had the physical and chemical properties they were looking for. They settled on a mixture of two CAGE (choline and geranic acid) and CAPA (choline and phenylpropanoic acid) that helped associated siRNA molecules retain their structural integrity and led to increased siRNA penetration into pig skin in vitro. When they applied the CAGE+CAPA mixture as a thick topical liquid to the skin of living mice, they observed no inflammation or irritation, indicating that it was non-toxic.

Because ILs are a fairly new material, predicting their interactions with the cargoes they are meant to deliver is challenging. The researchers collaborated with co-author Charles Reilly, a senior staff scientist in the Bioinspired Therapeutics & Diagnostics platform at the Wyss Institute, to perform molecular dynamics simulations to model and understand how the CAGE+CAPA solution would interact with siRNA and cell membranes at the molecular level. The observations from those simulations predicted that this IL-siRNA complex had superior stability due to its component ions strong chemical interactions with the RNA base pairs. The model also suggested that it led to higher penetration of cell membranes because the ions in the IL were able to pack closely together, forming aggregates that augmented the complexs ability to disrupt the membrane and allow the siRNAs entry.

Armed with an effective delivery vehicle, the team then coupled it with a specific siRNA designed to silence a gene called NFKBIZ, which has been implicated in the upregulation of a number of inflammatory molecules that are involved in psoriasis. They applied the CAGE+CAPA mixture along with the siRNA to the skin of mice with a psoriasis-like condition for four days, then compared those mice to others that had received CAGE+CAPA with a control siRNA, CAGE+CAPA alone, or no treatment.

The mice that were given the NFKBIZ siRNA treatment had reduced epidermal thickening, skin discoloration, and keratin overgrowth compared to the other experimental groups, as well as less redness and scaling. They also displayed a significant reduction in the expression of NFKBIZ and other psoriasis-related gene products in their skin cells, demonstrating for the first time that IL-siRNA complexes can induce a therapeutic effect at both molecular and macroscopic levels by silencing a target gene in vivo following topical administration.

Topical creams have been used to treat skin conditions for hundreds of years, but the skin is a very effective barrier against most substances, which limits their effectiveness. Being able to bridge that barrier to deliver nucleic acid therapeutics directly to skin cells is a huge accomplishment in the quest for targeted, effective therapeutics, said corresponding author Samir Mitragotri, who is a core faculty member at the Wyss Institute and the Hiller Professor of Bioengineering and Hansjrg Wyss Professor of Biologically Inspired Engineering at SEAS.

This IL-based delivery platform can be easily scaled up and tuned to interface with a variety of therapeutic molecules, including DNA and antibodies. It could also empower transdermal drug delivery for the treatment of other dermatologic skin conditions including eczema, and improve the long-term efficacy of therapies by targeting genes that mediate multiple disease pathways.

Based on the encouraging results from this study, Mitragotris lab is initiating new collaborations with researchers at various institutions focusing on understanding local and systemic mechanisms associated with autoimmune and inflammatory diseases in the skin.

Many of the innovations that biologists have been using in research for years have significant clinical potential, but most havent achieved it because of fundamental limiting factors such as, in this case, the barrier posed by the skin. This creative solution to this drug delivery problem holds great promise for enabling a new class of effective treatments that are long overdue, said the Wyss Institutes Founding Director and co-author of the paper Donald Ingber, who is also the Judah Folkman Professor of Vascular Biologyat Harvard Medical School and Boston Childrens Hospital, and Professor of Bioengineering at SEAS.

Additional authors of the paper include Ninad Kumbhojkar and Anvay Ukidve from the Wyss Institute and SEAS, and Vimisha Dharamdasani, formerly of the Wyss Institute and SEAS and currently at the University of Cambridge.

This research was supported by The Leo Foundation and the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Here is the original post:

Treatment significantly reduces symptoms of psoriasis in mice - Harvard Gazette

EC approves subcutaneous formulation of Remsima – European Pharmaceutical Review

The European Commission has granted marketing authorisation to Celltrions Remsima(infliximab, CT-P13) subcutaneous formulation.

The EuropeanCommission (EC) has granted marketing authorisation for the Remsima(infliximab, CT-P13) subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohns disease, ulcerative colitis, psoriatic arthritis and psoriasis.

Granted to Celltrion Healthcare, the approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of theEuropeanMedicines Agency (EMA)in June and is based on data from a pivotal study comparing the pharmacokinetics, efficacy and safety of the subcutaneous and intravenous (IV) formulations ofRemsimain people with active Crohns disease and ulcerative colitis, throughout a one year treatment period.

Based on the results of the pivotal study, a 120mg fixed dose of Remsima subcutaneoushas been approved for usein theEU inadults regardless of body weight,inboth existing and newly addedindications.

We are pleased to announce this important regulatory milestone earlier than we expected, with theECprioritising review of this important new administration option. We will accelerate the launch process on a country-by-country basisinorder to expand treatment options for patients with chronicinflammatory diseases such asinflammatory bowel disease and ankylosing spondylitis, said Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We will do our best to makeRemsima subcutaneous available as early as possible and hope this medication will contribute to minimising the risksinvolved with administering medical treatments during the COVID-19 pandemic.

According to the company, Celltrion anticipates receiving approval of Remsima subcutaneousin97 countries,including 31 countriesinEurope.

Read more here:

EC approves subcutaneous formulation of Remsima - European Pharmaceutical Review

Brodalumab for the Treatment of Psoriasis in Patients With HIV – Dermatology Advisor

Home Topics Psoriasis

Brodalumab may be an effective treatment for refractory psoriasis in patients with human immunodeficiency virus (HIV), suggests case study data published in Dermatologic Therapy.

Investigators described the case of a 62-year-old man with HIV who presented with worsening and persistent plaque psoriasis. His Psoriasis Area and Severity Index (PASI) score was 20.0, indicating moderate to severe disease. Erythema and scaling were observed in large areas on the scalp, trunk, and extremities. The patient was taking highly active antiretroviral therapy (HAART) for HIV and had serological evidence of past co-infection with hepatitis B and C. Thepatient had tried ultraviolet B phototherapy and cyclosporine for psoriasis. Cyclosporine was discontinued due to loss of efficacy and replaced with ustekinumab, which also became ineffective after 1 year.

The patient was started on brodalumab at the recommended dosage of 210 mg every 2 weeks. Marked improvement in plaque psoriasis was observed; a PASI score of 0 was achieved after 6 weeks of treatment. Sustained remission was observed at 6 months. Control of HIV was maintained, with no opportunistic infections or laboratory abnormalities over follow-up.

Data from this case suggest that brodalumab may be an option for patients with HIV who have exhausted other psoriasis therapies. However, administration of an IL-17 inhibitor to a patient with HIV must be done with caution, due to the role of IL-17 in preventing candidiasis. Patients with HIV are highly susceptible to Candida infection, although HAART decreases this susceptibility. The current patient did not experience candidiasis. [A]dditional experience is required before IL-17 inhibitors can be regarded as a standard therapy in moderate to severe HIV-associated psoriasis, investigators wrote.

Reference

Di Lernia V, Casanova DM, Ricci C. Brodalumab: another helpful option for HIV-positive psoriatic patients? [published online June 25, 2020]. Dermatol Ther. doi: 10.1111/dth.13895

Please login or register first to view this content.

LoginRegister

Read the original here:

Brodalumab for the Treatment of Psoriasis in Patients With HIV - Dermatology Advisor

MC2 Therapeutics Announces US Food and Drug Administration Approval of Wynzora Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)…

COPENHAGEN, Denmark, July 22, 2020 / B3C newswire / -- MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older.

The FDA approval is based on the results of the US Phase 3 clinical trial (1) against active comparator Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%). A total of 794 patients were randomized in this trial and the primary efficacy endpoint was the proportion of patients with PGA treatment success at week 8 defined as at least a 2-grade improvement from baseline in PGA to clear or almost clear. The difference in PGA treatment success to the active comparator was 14.6% (95% CI; 7.6%, 21.6%) in favor of Wynzora Cream.

Reduction of itch as defined by at least a 4-point improvement in the 11-point peak pruritus numeric rating scale (NRS) from baseline to week 4 was assessed among patients who had at least a peak pruritus NRS score of 4 at baseline. A higher proportion of patients achieved at least a 4-point improvement in the peak pruritus NRS score at week 4 in the Wynzora Cream group (60.3%) compared to vehicle (21.4%).

Wynzora Cream is a novel topical treatment for plaque psoriasis which offers a unique combination of high efficacy, favorable safety and excellent treatment convenience in a single product, said Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, and lead principal investigator in the study.

Studies show that more than half of psoriasis patients are dissatisfied with their treatment and that a large proportion of patients are not treated at all (2).

The FDA approval marks an important milestone for patients with plaque psoriasis", stated Jesper J. Lange, CEO of MC2 Therapeutics and continued: "Our PAD Technology has uniquely enabled us to develop Wynzora Cream with no compromises. It drives the compelling efficacy and safety data of Wynzora Cream and transforms that data into impact for patients through a convenient formulation that allows patients to move on within minutes of a morning routine. It puts patients back in control of therapy and daily life."

Founder and Executive Chairman of MC2 Therapeutics, Mads Clausen concurred: "Wynzora is a prime example of what we envision PAD Technology can do to help patients, physicians and payers release the full potential of topical therapies in real world settings."

With the US approval, the recent submission of its marketing authorization application of Wynzora Cream in EU, and its ongoing interactions with payers, physicians and patient organizations MC2 Therapeutics is well on track to launch Wynzora Cream in major territories. In addition, MC2 Therapeutics continues development of its pipeline of new topical therapies within major chronic inflammatory indications such as atopic dermatitis, uremic pruritus, lichen sclerosus and dry eye.

About Plaque PsoriasisPsoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of plaque psoriasis on peoples lives can be immense as it affects the appearance of the skin with red, scaly plaques. According to the National Psoriasis Foundation, itch is present in between 70 and 90 percent ofpsoriasispatients, and together with flaking and scaling, itching is the most burdensome symptom to patients (3,4,5). The appearance of flares of psoriasis can be unpredictable and affects people of all ages. With a reported prevalence of 2-4% of the population psoriasis constitutes a serious health problem with more than 100 million individuals affected worldwide. More than 90% of patients receiving treatment use topical drugs. Patients with psoriatic disease are at an elevated risk of developing other chronic and serious health conditions, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression (5).

About Wynzora Cream Wynzora Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. Wynzora Cream is based on PAD Technology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in a convenient-to-use aqueous formulation. In the phase 3 trials conducted at multiple sites in the US and the EU, Wynzora Cream has demonstrated a unique combination of compelling clinical efficacy, a favorable safety profile and high convenience. These features of Wynzora Cream hold promise to lead to less treatment discontinuation and overall better patient satisfaction in topical treatment of plaque psoriasis in the real-world setting.

Indication and UsageWynzora (calcipotriene and betamethasone dipropionate) Cream is a prescription medicine indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

Apply WynzoraCream to affected areas once daily for up to 8 weeks and not more than 100 grams per week. Patients should stop treatment when the plaque psoriasis is under control unless a healthcare provider gives other instructions.

Wynzora Cream is for use on skin only (topical). Do not get Wynzora Cream near or in your mouth, eyes, or vagina. Avoid using Wynzora Cream on your face, groin, or armpits, or if you have thinning of your skin (atrophy) at the treatment site.

It is not known if Wynzora Cream is safe and effective in children.

Important Safety InformationTell your healthcare provider about all your medical conditions and all the medicines you take, including any corticosteroid medicines and any other products containing calcipotriene.

Do not use other products containing calcipotriene or a corticosteroid medicine without talking to your healthcare provider first.

Wynzora Cream may cause side effects, including:

The most common side effects include upper respiratory infection, headache, and application site irritation. These are not all the possible side effects. Call your healthcare provider for medical advice about side effects.

This summary is not comprehensive. Visit http://www.wynzora.com to obtain the FDA-approved Full Prescribing Information.

About PAD TechnologyPAD Technology formulations are tailor-made to meet the target product profile for a selected product candidate. PAD Technology enables the mixing of oil and water into a cream using just a fraction of the emulsifier required in conventional creams and lotions. Key features of PAD Technology formulations are high penetration of active ingredients to the target tissue, improved solubility and stability of active ingredients, high tolerability and excellent treatment convenience.

About MC2 TherapeuticsMC2 Therapeutics is a privately held commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions. Using its PAD Technology it aims to set a new standard of treatment experience for patients and to release the full potential of novel topical drugs for the benefit of patients, physicians, payers and societies. PAD Technology is the basis for its innovative pipeline of drug candidates within atopic dermatitis, uremic pruritus, lichen sclerosus, and dry eye.

Contacts

MC2 TherapeuticsInvestors: Lonni Goltermann+45 2018 1111 This email address is being protected from spambots. You need JavaScript enabled to view it.

MediaEU: Molecule A/S: Mette Thorn Sorensen, +45 4138 4300 or This email address is being protected from spambots. You need JavaScript enabled to view it.US: Amy Phillips, +1 412.327.9499 or This email address is being protected from spambots. You need JavaScript enabled to view it.

References:

1. Clinical trial ID: NCT033087992. Armstrong et al. JAMA Dermatol. 2013;149(10):1180-11853. http://www.psoriasis.org/life-with-psoriasis/managing-itch (accessed July 13th, 2020)4. The Voice of the Patient, Psoriasis. FDA Public Meeting Report, 20165. WHO Global report on Psoriasis 2016

Keywords: Humans; betamethasone dipropionate, calcipotriol; calcipotriene; Prostaglandins A; Patient Satisfaction; Drug Users; United States Food and Drug Administration; Betamethasone; Calcitriol; betamethasone-17,21-dipropionate; Taclonex; Psoriasis; Drug Combinations; Treatment Outcome; Marketing

Published by B3C newswire and shared through Newronic

Read this article:

MC2 Therapeutics Announces US Food and Drug Administration Approval of Wynzora Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)...

European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC, for an additional five…

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima (infliximab, CT-P13) subcutaneous (SC) formulation for the treatment of adult patients with ankylosing spondylitis, Crohns disease, ulcerative colitis, psoriatic arthritis and psoriasis.1

The approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June and is based on data from a pivotal study comparing the pharmacokinetics, efficacy and safety of the SC and intravenous (IV) formulations of Remsima in people with active Crohns disease and ulcerative colitis, throughout a 1-year treatment period.2,3 Based on the results of the pivotal study, a 120 mg fixed dose of Remsima SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications.

Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany said: The subcutaneous formulation of Remsima (Remsima SC) has been shown to have very high efficacy, and favourable data, which are fully comparable to the efficacy and safety profile of the IV formulation. Todays approval marks an important progress for the gastroenterology community as it means that treatment can now be administered in significantly less time, thereby providing patients more flexibility and control over how they receive their treatment.

We are pleased to announce this important regulatory milestone earlier than we expected, with the European Commission prioritising review of this important new administration option. We will accelerate the launch process on a country-by-country basis in order to expand treatment options for patients with chronic inflammatory diseases such as inflammatory bowel disease and ankylosing spondylitis, said Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We will do our best to make Remsima SC available as early as possible and hope this medication will contribute to minimising the risks involved with administering medical treatments during the COVID-19 pandemic.

Celltrion anticipates receiving approval of Remsima SC in 97 countries, including 31 countries in Europe.

-- ENDS --

Notes to Editors:

About Remsima (CT-P13) intravenous (IV) formulation1Remsima IV is usually given as 3 mg per kg/body weight in rheumatoid arthritis (RA) and as 5 mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards.

About Remsima CT-P13 subcutaneous (SC) formulation4,5A 120 mg fixed dose of Remsima SC has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications for the IV formulation. Remsima SC has three administration options; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard. The SC formulation has the potential to enhance treatment options for the use of infliximab biosimilar by providing high consistency in drug exposure and a convenient method of administration.

About CT-P13 (biosimilar infliximab)CT-P13 is developed and manufactured by Celltrion, Inc. and was the worlds first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including RA and IBD. It was approved by the EC under the trade name Remsima in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra. CT-P13 is approved in more than 94 countries (as of July 2020) including the US, Canada, Japan and throughout Europe.

About Celltrion HealthcareCelltrion Healthcare is committed to delivering innovative and affordable medications to promote patients access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

Forward-looking statement disclaimerCertain information set forth in this press release contains statements related to our future business and financial performance, and future events or developments involving Celltrion Healthcare, that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as will, has potential to, brings, if approved, would, could, opportunity, hope, is considering the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand managements beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or managements estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

1 European Medicines Agency Summary of Product Characteristics (SmPC). Remsima.

2 Reinisch W, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase 1 open-label randomised controlled trial in patients with active Crohns disease. European Crohns and Colitis Organisation 2019. Abstract no: A-1103.

3 Ben-Horin S, et al. A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohns disease and ulcerative colitis. Oral presentation (OP24). Presented at ECCO 2020.

4 Yoo DH, Jaworski J, Matyska-Piekarska E et al. A Novel Formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: One-year results from part one of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (FRI0128). Presented at EULAR 2019.

5 Westhovens R, Wiland P, Zawadzki M et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (SAT0170). Presented at EULAR 2019.

More here:

European Commission grants marketing authorisation for world's first subcutaneous formulation of infliximab, Remsima SC, for an additional five...

Psoriasis Drug Being Used To Treat COVID-19; Why Itolizumab? – Inventiva

The year 2020 began with a not-so-great scenario that escalated rapidly into a pandemic that has crippled the functioning of the world. A lot has happened over the course of these past 4 months with a large number of people losing their lives to a microscopic virus. Coronavirus and COVID-19 are words that are familiar to every person in the world since it has made a huge impact on everything that rules peoples hectic lives; Business, economy and simply put, their way of living. The novelty of the virus is a research field in itself with scientists looking into its morphology and genetic structure, discovering new facts about this unknown microorganism. With most of the people who got affected being asymptomatic, scientists also have to work faster to detect the properties of this virus and easier ways to detect it to increase the number of people being tested per day. Therefore, it is a need of the hour for those susceptible to have a vaccine they can rely on that will be effective in helping them develop immunity against this virus. With the rush to develop a vaccine, many countries have applied for their drug compounds to be used for phase 3 or phase 4 trials. COVAX, an initiative by Gavi, a public-private partnership, to support the acceleration of the designing, development, and distribution of vaccines. With countries around the world trying to find a vaccine, about 130 vaccines are under testing in various phases. India is also actively taking part in this vaccine rush and has 2 possible drugs in different trial stages; Covaxin by Bharat Biotech and ZyCov-D by Zydus which are proving to be hopeful. Along with these two, Biocon, a global biopharma company based in Bangalore, recently announced that they have received a green flag from the Drug Controller General of India to release their novel biologic, Itolizumab (ALZUMAb) into the market for restricted emergency use in treating COVID-19 patients with moderate to severe complications.

But why is Itolizumab, a drug used in treating a chronic skin disease like psoriasis, being used to treat patients affected with COVID-19?

The SARS-CoV-2 virus affects individuals by triggering the immune system to generate a large number of cytokines which can attack the organs like lungs, etc. and can lead to multiple organ failure or death. Here is where Itolizumab seems to help the affected individuals.

Kiran Mazumder-Shaw, the Executive Chairperson of Biocon, said in a press release that this novel drug has been approved by the regulator, based on the promising data obtained from a pivotal two-arm, randomized trial involving 30 eligible patients across New Delhi and Mumbai. Out of these 30 patients, 20 were administered with Itolizumab with the best care, making them the test arm and the remaining 10 were not administered Itolizumab, making them the control arm. After a period of one month, the mortality rates were observed. The results were promising, as all 20 of the test arm patients experienced a full recovery. 3 patients out of the 10 in the control arm died.

Itolizumab proved itself to be efficient by meeting the key efficacy parameter of improving lung function without a hike oxygen flow as required by the patients in the control arm and also displayed suppression or reduction in the expression of clinical markers of inflammation. It has also worked tremendously in controlling moderate to severe ARDS (Acute Respiratory Distress Syndrome) induced by COVID-19 and has shown its efficacy in treating elder patients too. This clinical trial proved to be helpful in giving emergency treatment options to patients to reduce complications. Itolizumab, the psoriasis drug turned COVID-19 treatment, is shown to work best if administered before the cytokine release begins and helps to prevent the cytokine storm from intensifying.

This drug can be the best bet since it already is available in the market for the treatment of psoriasis, implying the fact that it is safe for human usage which has been proven by the 4 phase trials that were conducted before its release in 2013 by Biocon. Itolizumab acts by binding to the CD6 receptor and modulating it to prevent the T-lymphocyte activation thereby reducing the cytokine storm that turns into a deadly immune response.

Biocon is very well known for its unique biologics and pharmaceutical products in India and has a lot of global connections, Equillium being one of them. Equillium, a biotechnology company is planning to initiate a global study of this novel drug, Itolizumab, to make sure a large number of people get benefitted within a short period. Equillium is partnering with Biocon for Itolizumab in U.S., Canada, Australia, and New Zealand.

Bruce Steel, the co-founder, and CEO of Equillium said that they are working with Biocon to assess the further processes involved in accelerating the use of Itolizumab to treat COVID-19 patients in the U.S and abroad. The drug is being evaluated at present under two INDs for treating acute graft-vs-host disease and lupus nephritis, plus a clinical study in uncontrolled asthma in Australia and New Zealand.

Similarly, Itolizumab has been used to treat COVID-19 patients in Cuba too. The reports from Cuba were similar to the one obtained in the trial done in India and it shows a very low mortality rate in the patients who were administered with Itolizumab. The dosage being administered is a 25mg/5ml formulation at the rate of 4 vials per patient. Each vial costs Rs. 7,950. Therefore, the total dosage costs around Rs. 35,000.

The success and approval of Itolizumab show us that we can still hope for a better tomorrow with many individuals carrying out endless research works to find a solution. The efforts are enormous and we can only hope for them to be fruitful. With vaccines under trial and testing, the best we, as general citizens, can do is to stay calm and help others do the same. It is our responsibility to take enough care of our health and in this case, the health of our loved ones too.

Like Loading...

Related

Go here to see the original:

Psoriasis Drug Being Used To Treat COVID-19; Why Itolizumab? - Inventiva

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies – DocWire News

This article was originally published here

J Dermatolog Treat. 2020 Jul 24:1-14. doi: 10.1080/09546634.2020.1800578. Online ahead of print.

ABSTRACT

Background. The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide.Objective. To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics.Methods. A telephone survey was conducted in May 4-10, 2020 about the Italian lockdown period (March 09th May 03rd 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS).Results. 226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity.Conclusion. Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease.

PMID:32705945 | DOI:10.1080/09546634.2020.1800578

See the rest here:

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies - DocWire News

How to identify and treat strange things that might be happening on your skin – Las Vegas Sun

Shutterstock.com

By C. Moon Reed (contact)

Saturday, July 25, 2020 | 2 a.m.

Skin. Its our bodys biggest organ. Our protective envelope exists to keep the outside world out and the inside in. And yet its easy to ignore, up until the moment something goes wrong. Whats that weird rash? Who knows? Sure, you can use a phone filter to make your skin look great, but its better to address the problem and enjoy clear skin.

Weve rounded up info on some of the most common skin conditions that affect mankind, but this shouldnt replace professional medical advice. If you think something looks wrong, please consult a doctor.

Prevention is the best cure, so follow these simple steps to keep your skin healthy and happy.

Wash your hands.

Practice good hygiene.

Manage stress.

Eat a healthy diet.

Sleep enough.

Moisturize to prevent dry, cracked skin.

Dont share personal items like towels, razors and nail clippers.

Avoid touching your face.

Dont pick at, shave over, pop or scratch irritated skin, no matter how tempting.

Dont touch other peoples skin lesions.

Cover skin wounds, warts, etc. to speed healing and prevent cross-contamination.

Wear flip-flops around swimming pools and public showers.

Protect yourself from sun damage.

ACNE

Its the bane of pubescence. But pimples can linger beyond the teenage years.

Who: Everybody. Its the most common skin issue in the United States.

Cause: Pores clogged by dead skin cells get infected by a common skin bacteria, P. acnes. Risk factors include genetics, hormones, being female.

Symptoms: From cysts to blackheads to pustules and whiteheads, these blemishes can plague the face, chest, back, arms and buttocksand lead to scarring and dark spots.

Contagious? No.

Treatment: Start with over-the-counter topical treatments and see a dermatologist for prescription treatment if your acne is severe or not responding to other efforts. Do not pop pimples; it can make them worse and cause scarring.

CONTACT DERMATITIS

A general term for the type of rash one gets when skin comes into contact with an irritant.

Who: Anybody, but allergies are a risk factor.

Cause: Seasonal allergies; allergies to cheap jewelry (generally with nickel), cosmetics, detergents, medications, tattoo pigments, etc.

Symptoms: Itching, redness, swelling.

Contagious? No.

Treatment: Remove the irritant, and avoid future contact.

DANDRUFF

A type of dermatitis (seborrheic) that mainly affects the scalp.

Who: Mostly people with genetic predispositions, immune or nutrition issues.

Cause: Genetics, environmental factors, dry skin, stress.

Symptoms:Itching, flaking, discoloration of the skin.

Contagious? No.

Treatment: Medicated dandruff shampoo; shampoo daily; eat a healthy diet; get some sun; apply tea tree oil. Seek prescription treatments if the above doesnt help.

ECZEMA

Think of this chronic skin condition like asthma of the skin. Skin can be normal, and then suffer from outbreaks, like an allergic reaction.

Who: Anybody, but those with asthma or allergies are at higher risk.

Cause: Genetics, skin irritation or damage, immune issues.

Symptoms: Dryness, redness, itching, cracking, bleeding, infection.

Contagious? No.

Treatment: Hydrocortisone, antihistamines, steroid creams, laser therapy, immunosuppressants.

KERATOSIS PILARIS

An inherited skin condition that can make the upper arms, thighs, buttocks and/or cheeks appear to have goosebumps or whiteheads.

Cause: Genetics, worsened by dry environments.

Who: More common in children and young adults and generally resolves itself with age.

Symptoms: Painless, but can cause bumps and coarse skin.

Contagious? No.

Treatment: Exfoliate and moisturize; salicylic acid, topical retinoids.

MOLES

Mostly everybody has a mole somewhere or other. Generally, these pigmented skin growths are harmless, but some can be risk factors for melanoma (skin cancer).

Who: Almost everybody.

Cause: Irregular or clumpy growth of pigmented skin cells.

Symptoms: Beware of moles that are asymmetrical, oddly shaped, multicolored, larger than a pencil eraser and/or quickly changing, as these can be signs of melanoma.

Contagious? No.

Treatment: If your moles seem irregular, see a doctor immediately. Most moles dont require treatment, but if needed, they can be surgically removed by a dermatologist. In general, its a good idea to monitor your moles over time, just to make sure they dont turn against you.

MOLLUSCUM CONTAGIOSUM

This skin disease is caused by a poxvirus that lives in the upper layer of the skin.

Who: Anybody, but people with compromised immune systems are at higher risk.

Cause: Viral infection spread via physical contact (either skin-to-skin or via shared objects, such as towels or toys).

Symptoms: Itching, redness, small bumps with a pearly appearance.

Contagious? Yes, but your body can completely clear the infection.

Treatment: The disease typically clears on its own in six months to four years. A medical professional can help remove the lesions; do not attempt on your own.

PSORIASIS

Skin generally takes weeks to grow, but with this skin condition, it grows at hyperspeed, causing significant irritation.

Who: Genetics combined with triggering events such as stress, weather and/or medication.

Cause: An overactive immune system, generally.

Symptoms: Most people develop plaque psoriasis, which consists of scaly, raised patches that can look silver. They are very itchy, but scratching makes it worse. Other types of psoriasis include rashes and irritation on different parts of the body.

Contagious? No.

Treatment: Prescription medication, including lotions, pills and injections.

ROSACEA

Santa Claus is famous for his rosy cheeks. But what you took for Christmas cheer is most likely the skin condition rosacea.

Who: Older people, mostly women, with fair skin.

Cause: Genetics, acne is a risk factor, spicy foods, stress, sunlight.

Symptoms: Redness on the cheeks and nose, enlarged blood vessels, hot skin, irritated eyes, swollen nose.

Contagious? No.

Treatment: Antibiotics, laser therapy, surgery.

WARTS

A skin growth caused by the human papillomavirus (HPV).

Who: Anybody, but nail biting, hangnails, broken skin, shaving and weakened immune systems are risk factors.

Cause: Physical contact (skin-to-skin or with a contaminated object).

Symptoms: Depending on the type of wart, the growth can appear on the hands, fingers, feet, face, genitals and, really, anywhere.

Contagious? Yes.

Treatment: Can eventually resolve on its own; over-the-counter treatments available; dermatologist can treat with excision, electrosurgery, cryotherapy and more.

This story appeared in Las VegasWeekly.

Continued here:

How to identify and treat strange things that might be happening on your skin - Las Vegas Sun

Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis – AJMC.com Managed Markets Network

Psoriatic arthritis and psoriasis have high economic burdens and the total annual costs were similar between the 2 diseases, but the combination of both yielded the highest costs, according to an abstract published at the European League Against Rheumatism annual meeting.

The researchers analyzed 318 patients with psoriasis (n = 196), PsA (n = 43), or both (n = 79) in the COEPSO (Evaluation of Costs in patients with Psoriatic Disease) trial, an observational, retrospective, cross-sectional study in 22 Spanish centers from February 2017 to February 2018.

The authors obtained information from the year prior to the study on direct nonhealth care services (including social services, home care, and private health and nonhealth professionals), as well as indirect and total costs (direct nonhealth care and indirect costs) related to the disease. They calculated out-of-pocket costs, which were specified directly by the patients, and loss of productivity costs, which were gauged by the average salaries for the occupation specific by the patients.

Patients with both psoriasis and PsA had higher annual total costs than patients who only had 1 disease (75.5% higher than patients with psoriasis and 60.9% higher than patients with PsA). However, the total costs for patients with psoriasis and PsA were similar.

The average annual total cost per patient was 1042.71 ($1186.64) for psoriasis, 1137.84 ($1294.90) for PsA, and 1830.26 ($2082.89) for both. The breakdown of direct nonhealth care costs vs indirect costs were:

PsA and [psoriasis] have proved to be diseases with a high economic burden, and the total costs were mainly driven by direct non-healthcare costs, the authors concluded.

Reference

Vincente E, Castaeda S, Llamas Velasco M, et al. Cost of illness in patients with psoriasis and psoriatic arthritis. COEPSO Study. Presented at: EULAR 2020; June 3-6, 2020; Abstract OP0262-HPR. https://ard.bmj.com/content/79/Suppl_1/164.2

Follow this link:

Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis - AJMC.com Managed Markets Network

The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients? – The Hindu

The story so far: On July 11, pharma major Biocon announced that it had received the approval of the Drugs Controller General of India (DCGI) to market Itolizumab for treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome patients due to COVID-19. Itolizumab is a monoclonal antibody which is used to treat acute psoriasis.

Monoclonal antibodies are proteins cloned in the lab to mimic antibodies produced by the immune system to counter an infection. They have their genesis in serum, the colourless constituent of blood that contains antibodies. These proteins bind to an antigen, the fragment of an infectious virus in the case of SARS-CoV-2, and either destroy it or block its action. In the case of COVID-19, there are yet no proven drugs to treat moderate or severe manifestations of the disease. Among the therapies being tested is convalescent plasma, which is a constituent of blood and recovered from those who have successfully fought the disease. This blood contains antibodies produced within a week or two of being infected. While plasma therapy involves injecting this entire antibody-soup into another sick patient, a monoclonal antibody can be made by isolating specific antibodies and multiplying them via various techniques. Isolating plasma and serum is laborious and time-consuming when it must be administered to every patient. However, since 1975, several techniques have been perfected that allow antibodies once isolated to be easily replicated. These are stored in vials and can be injected into patients.

Also read | Biocons COVID-19 drug tested on too few patients to reliably conclude on benefits, say experts

While eight in 10 of those infected by the disease recover with little more than a few days of cough and fever, about one in 10 can manifest severe systems of the disease irrespective of their age and medical history. Experts are not sure why, but have observed that many who died were victims of a cytokine storm when the immune system goes into overdrive to flush out the virus. Pro-inflammatory cytokines recruit a host of specialised immune system cells to neutralise antigens. However, these cytokines can aggravate inflammation and injury in lung cells as well as in several other organs. A challenge in treatment is how to prevent this over-reaction. One method is to use antibodies that can block a particular protein, called CD6. They are found on the surface of T-cells, a class of cells that are a central prong in the bodys defence system.

Experts say if this CD-6 is suppressed, it will prevent the T-cells from releasing a cytokine cascade and thus better regulate the immune system. There is also a lot of research going on in using such antibodies to prevent the replication of the virus. Since last month there have been reports from laboratories from nearly everywhere, reporting the presence of one or more antibodies that could be used to block the spike protein, the key the coronavirus uses to infiltrate lung cells and proliferate. Before monoclonal antibodies were roped into discussions surrounding COVID-19, research has focused on deriving the right kind of antibodies that specifically bind onto regions of interest. These underpin the design of cancer therapies or fixes for autoimmune diseases, rheumatoid arthritis or acute psoriasis.

Sometimes antibodies are known to help viral entry and replication in target cells which can worsen the disease. This is why they need careful evaluation.

Also read | No evidence yet that itolizumab, tocilizumab reduces deaths: ICMR head

Itolizumab is an approved drug for acute psoriasis since 2013 and has passed safety and efficacy trials for that disease in over 500 patients. However, independent experts have pointed out that the efficacy of the drug in treating COVID-caused Acute Respiratory Disease Syndrome has not been conclusively demonstrated because it has, as part of a clinical trial, only been tested on 30 patients. However, the drug has been approved by the DCGI for emergency use in the treatment of moderate to severely-ill patients as per the discretion of physicians. The DCGI also directed Biocon to conduct a phase-4 study it must monitor it for adverse reactions or side-effects after it has been administered in large groups of patients and report back to the authorities. Experts pointed out that the normal process for approving a drug includes a phase-3 trial, where the drugs safety and efficacy are first evaluated in the wider population. Officials at Biocon claim they plan to test the drug in the United States, Canada, Australia and New Zealand. Several doctors, at a press conference organised by Biocon, said their patients had benefitted from the drug but mostly when they were yet to reach a stage before requiring ventilators or external oxygen support. The drug cost a little under 8,000 for every vial. Generally, four vials are necessary for treatment, company officials said.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Follow this link:

The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients? - The Hindu

Analyzing Impacts Of COVID-19 On Psoriasis Market Effects, Aftermath And Forecast To 2026 – Cole of Duty

The global Psoriasis market focuses on encompassing major statistical evidence for the Psoriasis industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Psoriasis study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Psoriasis industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Psoriasis market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Psoriasis report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Psoriasis market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Psoriasis Market report @ https://hongchunresearch.com/request-a-sample/40648

Key players in the global Psoriasis market covered in Chapter 4:, Celgene Corporation, Takeda Pharmaceutical Company Limited, Pfizer Inc., Stiefel Laboratories Inc., Amgen Inc., Biogen Idec, Novartis AG, Eli Lilly and Company, Johnson and Johnson (Janssen Biotech Inc.), AbbVie Inc.

In Chapter 11 and 13.3, on the basis of types, the Psoriasis market from 2015 to 2026 is primarily split into:, Systemic, Phototherapy, Topical Treatment, Others

In Chapter 12 and 13.4, on the basis of applications, the Psoriasis market from 2015 to 2026 covers:, Injectable, Tropical, Oral

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Psoriasis market study further highlights the segmentation of the Psoriasis industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Psoriasis report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Psoriasis market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Psoriasis market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Psoriasis industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Psoriasis Market Report with [emailprotected] https://hongchunresearch.com/report/psoriasis-market-40648

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Psoriasis Market

Chapter Four: Players Profiles

Chapter Five: Global Psoriasis Market Analysis by Regions

Chapter Six: North America Psoriasis Market Analysis by Countries

Chapter Seven: Europe Psoriasis Market Analysis by Countries

Chapter Eight: Asia-Pacific Psoriasis Market Analysis by Countries

Chapter Nine: Middle East and Africa Psoriasis Market Analysis by Countries

Chapter Ten: South America Psoriasis Market Analysis by Countries

Chapter Eleven: Global Psoriasis Market Segment by Types

Chapter Twelve: Global Psoriasis Market Segment by Applications12.1 Global Psoriasis Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Psoriasis Sales and Market Share by Applications (2015-2020)12.1.2 Global Psoriasis Revenue and Market Share by Applications (2015-2020)12.2 Injectable Sales, Revenue and Growth Rate (2015-2020)12.3 Tropical Sales, Revenue and Growth Rate (2015-2020)12.4 Oral Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Psoriasis Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/40648

List of tablesList of Tables and FiguresTable Global Psoriasis Market Size Growth Rate by Type (2020-2026)Figure Global Psoriasis Market Share by Type in 2019 & 2026Figure Systemic FeaturesFigure Phototherapy FeaturesFigure Topical Treatment FeaturesFigure Others FeaturesTable Global Psoriasis Market Size Growth by Application (2020-2026)Figure Global Psoriasis Market Share by Application in 2019 & 2026Figure Injectable DescriptionFigure Tropical DescriptionFigure Oral DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Psoriasis Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Psoriasis Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of PsoriasisFigure Production Process of PsoriasisFigure Manufacturing Cost Structure of PsoriasisFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Celgene Corporation ProfileTable Celgene Corporation Production, Value, Price, Gross Margin 2015-2020Table Takeda Pharmaceutical Company Limited ProfileTable Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Stiefel Laboratories Inc. ProfileTable Stiefel Laboratories Inc. Production, Value, Price, Gross Margin 2015-2020Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table Biogen Idec ProfileTable Biogen Idec Production, Value, Price, Gross Margin 2015-2020Table Novartis AG ProfileTable Novartis AG Production, Value, Price, Gross Margin 2015-2020Table Eli Lilly and Company ProfileTable Eli Lilly and Company Production, Value, Price, Gross Margin 2015-2020Table Johnson and Johnson (Janssen Biotech Inc.) ProfileTable Johnson and Johnson (Janssen Biotech Inc.) Production, Value, Price, Gross Margin 2015-2020Table AbbVie Inc. ProfileTable AbbVie Inc. Production, Value, Price, Gross Margin 2015-2020Figure Global Psoriasis Sales and Growth Rate (2015-2020)Figure Global Psoriasis Revenue ($) and Growth (2015-2020)Table Global Psoriasis Sales by Regions (2015-2020)Table Global Psoriasis Sales Market Share by Regions (2015-2020)Table Global Psoriasis Revenue ($) by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions in 2015Table Global Psoriasis Revenue Market Share by Regions in 2019Figure North America Psoriasis Sales and Growth Rate (2015-2020)Figure Europe Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Sales and Growth Rate (2015-2020)Figure South America Psoriasis Sales and Growth Rate (2015-2020)Figure North America Psoriasis Revenue ($) and Growth (2015-2020)Table North America Psoriasis Sales by Countries (2015-2020)Table North America Psoriasis Sales Market Share by Countries (2015-2020)Figure North America Psoriasis Sales Market Share by Countries in 2015Figure North America Psoriasis Sales Market Share by Countries in 2019Table North America Psoriasis Revenue ($) by Countries (2015-2020)Table North America Psoriasis Revenue Market Share by Countries (2015-2020)Figure North America Psoriasis Revenue Market Share by Countries in 2015Figure North America Psoriasis Revenue Market Share by Countries in 2019Figure United States Psoriasis Sales and Growth Rate (2015-2020)Figure Canada Psoriasis Sales and Growth Rate (2015-2020)Figure Mexico Psoriasis Sales and Growth (2015-2020)Figure Europe Psoriasis Revenue ($) Growth (2015-2020)Table Europe Psoriasis Sales by Countries (2015-2020)Table Europe Psoriasis Sales Market Share by Countries (2015-2020)Figure Europe Psoriasis Sales Market Share by Countries in 2015Figure Europe Psoriasis Sales Market Share by Countries in 2019Table Europe Psoriasis Revenue ($) by Countries (2015-2020)Table Europe Psoriasis Revenue Market Share by Countries (2015-2020)Figure Europe Psoriasis Revenue Market Share by Countries in 2015Figure Europe Psoriasis Revenue Market Share by Countries in 2019Figure Germany Psoriasis Sales and Growth Rate (2015-2020)Figure UK Psoriasis Sales and Growth Rate (2015-2020)Figure France Psoriasis Sales and Growth Rate (2015-2020)Figure Italy Psoriasis Sales and Growth Rate (2015-2020)Figure Spain Psoriasis Sales and Growth Rate (2015-2020)Figure Russia Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Revenue ($) and Growth (2015-2020)Table Asia-Pacific Psoriasis Sales by Countries (2015-2020)Table Asia-Pacific Psoriasis Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2019Table Asia-Pacific Psoriasis Revenue ($) by Countries (2015-2020)Table Asia-Pacific Psoriasis Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2019Figure China Psoriasis Sales and Growth Rate (2015-2020)Figure Japan Psoriasis Sales and Growth Rate (2015-2020)Figure South Korea Psoriasis Sales and Growth Rate (2015-2020)Figure Australia Psoriasis Sales and Growth Rate (2015-2020)Figure India Psoriasis Sales and Growth Rate (2015-2020)Figure Southeast Asia Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Originally posted here:

Analyzing Impacts Of COVID-19 On Psoriasis Market Effects, Aftermath And Forecast To 2026 - Cole of Duty

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 – PharmiWeb.com

Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become best-in-class based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical)

PDE4 compound series strengthens UNIONs pipeline and offers potential synergies at organizational, financial and commercial levels

Hellerup, Denmark, July 21, 2020 UNION therapeutics A/S (UNION) today announced the completion of a transaction with LEO Pharma A/S (LEO Pharma) to acquire the global rights for the LEO PDE4 inhibitor compound series to be re-named UNI500.

UNI500 is a series of phosphodiesterase type 4 (PDE4) inhibitors that were discovered by LEO Pharma. LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo in randomized, double-blinded, placebo-controlled clinical studies.

The acquisition of the PDE4 inhibitor compound series is perfectly aligned with UNIONs vision to build a sustainable pharmaceutical company and it complements our current clinical activities in immuno-dermatology. The acquisition substantially accelerates our growth trajectory and enables synergies at organizational, financial, and commercial levels. Above and beyond that, UNION considers compounds from the PDE4 inhibitor compound series to have best-in-class potential for the treatment of psoriasis and other immune-dermatological disorders, with an overarching aim to address unmet medical needs, said Rasmus Toft-Kehler, Chief Executive Officer of UNION.

Morten Sommer, Chief Scientific Officer, of UNION explains Orismilast has demonstrated promising effects in clinical studies suggesting that it could become an attractive oral treatment option for patients with psoriasis and other immune-dermatological disorders. Our ambition, based on demonstrated potency levels, is to develop orismilast as a best-in-class PDE4 inhibitor across multiple immune-related diseases. As a next step, UNION will finalize formulation efforts with orismilast and simultaneously evaluate priority indications for clinical advancement.

Thorsten Thormann, Vice President, Global Research at LEO Pharma added LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options.

Under the agreement, UNION will pay upfront, development and commercial milestones of up to 200 million USD, plus low single-digit royalties on sales. As part of the transaction, LEO Pharma also becomes a minority shareholder in UNION therapeutics.

About UNION therapeutics A/SUNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA.

About LEO Pharma A/S

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

ContactsMorten BoesenChief Financial Officer

Tel: +45 2381 5487

Email: info@uniontherapeutics.com

JW Communications

Julia Wilson

Tel: +44 781 8430877

Email: communications@uniontherapeutics.com

See the article here:

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 - PharmiWeb.com

Global Systemic Psoriasis Therapeutics Market Development and Trends Forecasts Report 2020-2026 – CueReport

Global Systemic Psoriasis Therapeutics market Size study report with COVID-19 effect is considered to be an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with the overall size of the Systemic Psoriasis Therapeutics industry, estimated from 2020 to 2026. The research report also provides a detailed overview of leading industry initiatives, potential market share and business-oriented planning, etc. The study discusses favorable factors related to current industrial conditions, levels of growth of the Systemic Psoriasis Therapeutics industry, demands, differentiable business-oriented approaches used by the manufacturers of the Systemic Psoriasis Therapeutics industry in brief about distinct tactics and futuristic prospects.

The research report on Systemic Psoriasis Therapeutics market provides a comparative study of the historical data with the changing market scenario to reveal the future roadmap of the industry. It offers detailed insights pertaining to the growth markers, challenges and opportunities residing in this industry vertical. A magnified view of the regional landscape and competitive terrain of this business sphere is also encompassed in the document. In addition, the report reevaluates the market behavior considering the impact of COVID-19 on the business landscape.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/24302

Systemic Psoriasis Therapeutics market rundown:

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/24302

An overview of regional terrain:

Competitive outlook of the Systemic Psoriasis Therapeutics market:

Other important takeaways from the Systemic Psoriasis Therapeutics market report:

The report answers important questions that companies may have when operating in the global Systemic Psoriasis Therapeutics market. Some of the questions are given below:

What will be the size of the global Systemic Psoriasis Therapeutics market in 2026?

What is the current CAGR of the global Systemic Psoriasis Therapeutics market?

Which product is expected to show the highest market growth?

Which are the top players currently operating in the global Systemic Psoriasis Therapeutics market?

Which application is projected to gain a lions share of the global Systemic Psoriasis Therapeutics market?

Will there be any changes in market competition during the forecast period?

Which region is foretold to create the most number of opportunities in the global Systemic Psoriasis Therapeutics market?

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/24302

See the original post here:

Global Systemic Psoriasis Therapeutics Market Development and Trends Forecasts Report 2020-2026 - CueReport

What Are the Medication Options for Psoriasis? – HealthCentral.com

On this page:BasicsTopical MedicationsOral TreatmentsBiologics

Theres no cure for psoriasis, but there are a lot of medications that can treat the chronic skin condition. Whether youre newly diagnosed or still searching for the right treatment (yup, sometimes theres a little trial and error), the number of choices can seem daunting. There are topicals, oral medications, and biologic drugs. While they all have the same overall goalclear your skinthey do it in different ways. Some medications soothe and calm an outbreak, while others prevent future flares. The treatment plan you end up on is often determined by your type of psoriasis, its severity and location, and your overall healthy history. Here, well walk you through all your options.

Psoriasis is a chronic condition that causes red, stinging patches or bumps on your arms, legs, and even your scalp. When you have this disease, your skin cells turn over faster than they should, leading to a buildup of cells on your body's surface that turn into those inflamed, scaly spots.

At first glance, it looks like a skin issue. And while thats true, experts say it starts on a deeper levelin your immune system. An overactive immune system, along with a genetic predisposition for psoriasis, and at least one other factor such as infection, obesity, or smoking are thought to be the driving forces behind the condition.

As we mentioned, there are several different types of psoriasis: plaque psoriasis (the most common type), scalp psoriasis, guttate, pustular, inverse, erythrodermic, and even psoriatic arthritis, which is a combo of psoriasis and arthritis. The medication youre prescribed is often determined by your type, and may include topical treatments, drugs taken orally, and injections. Let's start by taking a look at topical medications for psoriasis.

These creams, ointments, foams, shampoos, and lotions are applied directly to the affected areas, and are often prescribed for mild to moderate casespsoriasis that covers 1% to 10% of your body. Topical treatments can be used alone, or in combination with another treatment prescribed by your doctor. For example, you may use a cream along with an oral medication and/or light therapy. Topicals are used for these types of psoriasis:

The most common types of topical treatments prescribed for psoriasis include:

Corticosteroids work by reducing inflammation and redness. Theyre often prescribed to clear a current flare but wont necessarily stop your psoriasis from coming back in the future. There are various forms, including liquids, foams, and creams that come in various strengths. Examples include:

Side effects include:

These creams, liquids, and foams are believed to stop the overgrowth of skin cells, which may help prevent future psoriasis flares. They also help clear current patches by sloughing off scaly skin and flattening plaques so they are less noticeable.

Dovonex (calcipotriene) is a synthetic form of vitamin D that comes in a cream or a liquid for scalp psoriasis. You apply it twice a day for up to eight weeks.

Vectical (calcitriol) is a natural form of vitamin D that comes in an ointment formulation to use twice daily. While most topicals are okay to use during pregnancy, Vectical is not.

Enstilar (calcipotriene and betamethasone dipropionate) is a foam thats a combination of a synthetic form of vitamin D and a steroid. Its approved for adults only and used once a day for up to a month.

Taclonex (calcipotriene and betamethasone dipropionate) is a liquid vitamin D-steroid combo thats approved for use in children ages 12 and up. Use it once a day for up to a month.

Research has shown that using a vitamin D analogue with a corticosteroid may not only be more effective than using either one alone, but the combo can even reduce the side effects that can come with strong steroid use. But side effects can include:

Yes, the vitamin A derivatives that smooth wrinkles and clear acne can also help with psoriasis. Topical retinoids help alleviate redness, scaling, and inflammation, and regulate the high-speed skin-cell growth associated with the condition. Because of their risk of birth defects, retinoids should be avoided if youre pregnant or planning to become pregnant.

Tazorac (tazarotene), available as a gel or cream, is approved for adults and comes in two strengths. It is used once a day and can be applied daily for up to a year.

Duobrii (halobetasol propionate and tazarotene) is one of the newest topical medications. This combo product contains a vitamin A derivative (called tazarotene) with an anti-inflammatory lotion. You use it daily as needed.

Side effects include:

Anthralin is a man-made version of goa powder, a natural substance that comes from the araroba tree. Like many of the other topicals, this helps halt the excessive growth of skin cells and is approved for adults. It comes in a variety of formulations including a cream, ointment, and paste which can be used once a day on the skin. It also comes in a shampoo which can be used on the scalp. Anthralin-containing products include:

Side effects include:

Taken by mouth, oral medications target your overactive immune system (or parts of it) to reduce inflammation and/or slow down skin cell production. With so many choices, your doctor can help you find the best oral option for you to take alone or in combination with other forms of treatment like topicals, phototherapy, or biologics. Oral medications are most often prescribed for the following psoriasis types:

The most commonly prescribed oral options include:

Trexall and Rheumatrex (methotrexate) work by targeting and slowing the growth of skin cells. They come with a risk of toxicity, so theyre only taken once or twice a week, and not prescribed for long-term use. Methotrexate isnt safe to take if youre pregnant or nursing or have any blood issues like low white blood cell count or anemia.

Side effects include:

Gengraf (cyclosporine) was initially used as a medication to ward off organ rejection. It works on severe psoriasis by slowing an overactive immune system. The drug is taken daily either in pill form or a liquid that you dilute in juice.

Side effects: Cyclosporine can cause decreased kidney function, flu-like symptoms, high blood pressure, and cholesterol. This is another medication thats not safe while pregnant or nursing, and shouldnt be taken for longer than a year. Avoid cyclosporine if you take anti-cancer, anti-fungal, anti-convulsants, or anti-inflammatory medications, as well as antibiotics, aspirin, or ibuprofen.

Xeljanz (tofacitinib), one of the newer oral medications, inhibits a family of intracellular nonreceptors called Janus kinase, a.k.a. a JAK inhibitor. In doing so, it decreases cytokines, proteins that cause inflammation. By lowering inflammation in those with psoriasis, you get less symptoms.

Side effects include:

Soriatane (acitretin) is a form of vitamin A (a.k.a. a retinoid) that helps regulate those out-of-control skin cells. Its taken orally daily. If youre pregnant or planning to start a family within the next three years or have experienced sensitivity to retinoids in the past, this medication isnt an option for you.

Side effects include:

Otezla (apremilast) is one of the newest oral treatments. It works by reducing inflammation. Less inflammation may mean less outbreaks, or at least less severe ones. This cant be taken with some other medications such as phenobarbital and rifampin.

Side effects include:

Prednisone and Medrol (methylprednisone). Sometimes prescribed as pills or injections, these meds work by reducing inflammation and slowing cell growth. They help calm a flare-up but arent recommended for long-term use.

Side effects include:

These drugs are commonly prescribed (alone or along with other meds) for moderate-to-severe psoriasis because theyre so effectiveespecially the newer kids on the block like Skyrizi, Cimzia, and Ilumya.

Biologics are known as systemic treatments because they spread throughout the body and do their work from the inside out, but unlike other drugs that affect your entire immune system, these zero in on very specific partsvarious proteins or white blood cells that contribute to psoriasis such as tumor necrosis factor (TNF), interleukin 17, interleukin 23, and T-cells. By blocking these proteins and cells, the drugs can stop a psoriasis flare.

Interestingly, psoriasis biologics may help with other inflammatory issues such as heart disease. A recent study in JAMA Cardiology found that those who took biologics for psoriasis had a significant reduction in coronary inflammation, too.

Biologics are made from living cells of animals, humans, or bacteria and are given through an intravenous drip (IV) or injected in your thigh, upper arm, stomach, or butt either by a health care provider, caregiver, or yourself. (Dont worry, your M.D. will make sure you know exactly how to do this before sending you off to self-inject.)

Theyre used to treat these types of psoriasis:

There are several types of biologics:

Stelara (ustekinumab) is injected into your body to block a protein called IL-23 and IL-12. This helps ease the inflammation that can cause symptoms of both moderate to severe psoriasis and psoriatic arthritis. The drug requires two starter injections four weeks apart followed by four doses per year done 12 weeks apart.

Ilumya (tidrakizumab-asmn) and Skyrizi (risankizumab-rzaa) require two initial doses, four weeks apart, to block the IL-23 protein. This is followed by four doses per year, every 12 weeks.

Tremfya (guselkumab) also targets IL-23 with two starter doses four weeks apart and then every eight weeks.

Side effects are rare but include:

One cause of plaque psoriasis (which accounts for 80% of all psoriasis cases) is the excess production of a protein called tumor necrosis factor (TNF) which tells your skin cells to grow at an accelerated rate. These medications, which block TNF so that your skin cells grow more slowly, need to be taken over a long period of time to clear your skin.

Unlike some psoriasis medications, TNF inhibitors can be taken while pregnant or nursing (but of course, not without talking to your OB/GYN). However, youll want to avoid this category of biologics if you have multiple sclerosis (MS) or have an immediate relative with MS. Anti-TNF therapy has been associated with the demyelinating disease.

Cimzia (certolizumab pegol) can either be injected by yourself or you can have it injected at your doctors offices with two doses the first time, then two doses two weeks later, followed by two doses two weeks after that. Following these initial shots, you have one every other week.

Enbrel (etanercept) is unique because it is also approved for use in children. Although dosage can vary, you typically inject yourself with Enbrel twice a week for the first three months and then once a week for three months after that.

Humira (adalimumab) starts with two doses on day one and continues with one dose every other week. Cyltezo and Amjevita are approved biosimilars to Humira.

Remicade (infliximab) is given as an IV infusion that takes about two hours at your health care providers office. You begin with three starter doses administered during a six-week period, and then get one infusion every eight weeks. Inflectra and Renflexis are biosimilar.

Side effects are rare but include:

These biologics contain a human antibody that blocks a protein called interleukin 17 (IL 17), which causes inflammation and an immune response. Before prescribing these biologics, your M.D. will make sure you dont have latent tuberculosis, meaning you carry the tuberculosis bacteria but dont have an active disease. IL 17 inhibitors can trigger a case.

Cosentyx (secukinumab) is self-injected; two doses a week for four weeks and then once a month.

Siliq (brodalumab) targets four of the IL-17 proteins (others target just one). You take one dose weekly for three weeks and then one dose every two weeks. (Siliq carries a warning about suicidal behavior and thoughts.

Taltz (ixekizumab) is self-injected; two doses on the first day and then one injection every two weeks for three months. After that, you do it just once per month.

Side effects are rare but include:

These medications target T-cells, a type of white blood cell that causes inflammation.

Orencia (abatacept) is prescribed as a once-a-week shot for psoriatic arthritis, but it doesnt help with skin psoriasis.

Side effects include:

In some cases, your physician may prescribe a biologic along with another medication such as a topical treatment or oral medication. Some people develop anti-drug antibodies (ADAs) to biologics, making them less effective after a while. A review in the British Journal of Dermatology found that combining a biologic with the systemic oral medication methotrexate may help prevent ADAs.

Some medications are safe to take while pregnant or breastfeeding, while others, such as methotrexate, should be avoided. Discuss your options with your doctor so you can create a customized treatment plan.

You may be desperate to try anything to soothe your skin, but skip the fad diets, tanning beds, and Vicks VapoRubtheres little to no research verifying their efficacy, and they can irritate or dry out your skin.

Yes. Many of the medications are approved for both conditions, including the Cimzia, Enbrel, Humira, Stelara, Remicade, Cosentyx, methotrexate, Otezla, and systemic steroids.

Some people notice their biologic doesnt work as well over time. Experts say your body may have outsmarted the drug by creating antibodies against it. If your psoriasis is no longer responding to a certain drug, your doctor will likely switch you to something else.

See the article here:

What Are the Medication Options for Psoriasis? - HealthCentral.com

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 – BioSpace

HELLERUP, Denmark, July 21, 2020 /PRNewswire/ -- UNION therapeutics A/S ("UNION") today announced the completion of a transaction with LEO Pharma A/S (LEO Pharma) to acquire the global rights for the LEO PDE4 inhibitor compound series to be re-named UNI500.

UNI500 is a series of phosphodiesterase type 4 (PDE4) inhibitors that were discovered by LEO Pharma. LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo in randomized, double-blinded, placebo-controlled clinical studies.

"The acquisition of the PDE4 inhibitor compound series is perfectly aligned with UNION's vision to build a sustainable pharmaceutical company and it complements our current clinical activities in immuno-dermatology. The acquisition substantially accelerates our growth trajectory and enables synergies at organizational, financial, and commercial levels. Above and beyond that, UNION considers compounds from the PDE4 inhibitor compound series to have best-in-class potential for the treatment of psoriasis and other immune-dermatological disorders, with an overarching aim to address unmet medical needs", said Rasmus Toft-Kehler, Chief Executive Officer of UNION.

Morten Sommer, Chief Scientific Officer, of UNION explains "Orismilast has demonstrated promising effects in clinical studies suggesting that it could become an attractive oral treatment option for patients with psoriasis and other immune-dermatological disorders. Our ambition, based on demonstrated potency levels, is to develop orismilast as a best-in-class PDE4 inhibitor across multiple immune-related diseases. As a next step, UNION will finalize formulation efforts with orismilast and simultaneously evaluate priority indications for clinical advancement".

Thorsten Thormann, Vice President, Global Research at LEO Pharma added "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options".

Under the agreement, UNION will pay upfront, development and commercial milestones of up to 200 million USD, plus low single-digit royalties on sales. As part of the transaction, LEO Pharma also becomes a minority shareholder in UNION therapeutics.

About UNION therapeutics A/SUNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA.

About LEO Pharma A/SThe company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

ContactsMorten BoesenChief Financial OfficerTel: +45 2381 5487Email: info@uniontherapeutics.com

JW CommunicationsJulia WilsonTel: +44 781 8430877Email: communications@uniontherapeutics.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-cand,c3157569

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-candidate-orismilast-in-phase-2-301096733.html

SOURCE UNION therapeutics

Go here to see the original:

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 - BioSpace

5 effective home remedies to treat psoriasis – TheHealthSite

Psoriasis is a chronic skin disease in which the immune system triggers the overproduction of skin cells. It causes red, itchy scaly patches that most usually appear on the knees, elbows, trunk and scalp. However, they can develop anywhere on the body. Unfortunately, there is no cure for this condition. Treatments can only help manage symptoms. Psoriasis patches tend to flare up for a few weeks or months, then subside for a while or go into remission. Psoriasis is believed to be caused by immune system malfunction that causes the skin to regenerate at faster than normal rates, but what causes the immune system to malfunction isn't known yet. Both genetics and environmental factors are thought to play a role in the development of Psoriasis. If you have a parent with psoriasis, you are at risk of getting the disease. Some common psoriasis triggers include infections, such as strep throat or skin infections, cold or dry conditions, injury to the skin, smoking and alcohol consumption, stress, certain medications including high blood pressure medications and antimalarial drugs. Some home remedies may help relieve psoriasis symptoms, but it is always advisable to speak to a doctor first. These remedies tend to work best when used in combination with medical treatment.

More:

5 effective home remedies to treat psoriasis - TheHealthSite

I Live With Debilitating Psoriasis. Here’s How I Don’t Let It Defeat Me. – Men’s Health

Millions of people suffer from psoriasis, an autoimmune disease that causes painful patches of red or scaly skin called plaques to appear on the body. Flares can happen at any time, and they arent limited to spots that are easy to cover. Nor are they treatable with creams or antibiotics like other skin conditions such as eczema. Psoriasis isn't some simple rashIts a lifetime of struggle.

Those are the words of Jassem JasAhmed, a 29-year-old from London whose approach to that struggle is truly inspirational. Jass initial experience with psoriasis is a prime example of just how physically and emotionally debilitating the disease can be. He was diagnosed at 19 and soon found himself with nearly 90 percent of his body covered, and confined to his bed for nine months.

Jass was able to return to his active life, but the flares always returned. Then theyd get better, and then theyd come back, and the cycle would repeat. It still does.

But Jass wouldnt be defeated. After much trial and error and consultation with his doctors, Jass eventually found a course of treatment that suits him and his lifestyle. He also found a creative outlet to vent his anxieties: a vlog and YouTube channel where he chronicles every step of his journey. Jass doesnt sugar-coat anythinghis good days are right there next to his worse flare-ups, in all their high-definition detail. It wasnt long after posting his first video that Jass found himself with subscribers following along, asking for advice, or sending messages of thanks. Psoriasis so often carries embarrassment and shame; Jass shows people suffering from it that they arent alone. An accidental influencer perhaps, but as authentic as they come.

Wear it on your sleeve. Be proud of it, he says. I have psoriasis, it doesnt define me. Its a condition, its not who I am.

Check out the video above to learn more about living with psoriasis and how to retake control when life tries to push you off course.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Go here to read the rest:

I Live With Debilitating Psoriasis. Here's How I Don't Let It Defeat Me. - Men's Health